Preclinical data are also confirmed by a randomized, double blind, clinical placebo control trial on type 2 diabetic adults, where was shown a significant increase in postprandial GLP-1 concentration after butyrate supplementation and a decreasing trend was observed for homeostatic model assessment of insulin resistance (HOMA-IR) indices [ 167 ].
← all excerpts
The Protective Role of Butyrate against Obesity and Obesity-Related Diseases.
1
—
—